Neuronal intranuclear inclusion disease: two cases of dopa-responsive juvenile parkinsonism with drug-induced dyskinesia.
There are very few conditions that present with dopa-responsive juvenile parkinsonism. We present two such children with neuronal intranuclear inclusion disease (NIID) who had an initial good levodopa response that was soon complicated by disabling dopa-induced dyskinesia. One child was diagnosed by rectal biopsy in life, and the other diagnosis was confirmed at postmortem. In this patient, dopamine transporter imaging showed severely decreased binding of the radiotracer in the striatum on both sides. Bilateral subthalamic deep brain stimulation in this patient produced initial improvement, but this was not sustained. Both patients died within 10 years of symptom onset. As well as levodopa responsiveness with rapid onset of dyskinesia, clues to the diagnosis of NIID in patients presenting with parkinsonism include the presence of gaze-evoked nystagmus, early onset dysarthria and dysphagia and oculogyric crises. Differential diagnosis of clinical symptoms and neuropathological findings are discussed including the approach to rectal biopsy for early diagnosis.
Lai
Szu-Chia
SC
Neuroscience Research Center, Chang Gung Memorial Hospital, Chang Gung University College of Medicine, Taoyuan, Taiwan.
Jung
Shih-Ming
SM
Grattan-Smith
Padraic
P
Sugo
Ella
E
Lin
Yen-Wen
YW
Chen
Rou-Shayn
RS
Chen
Chiung-Chu
CC
Wu-Chou
Yah-Huei
YH
Lang
Anthony E
AE
Lu
Chin-Song
CS
D000293:Adolescent; D000978:Antiparkinson Agents / Q000009:adverse effects; D002648:Child; D004409:Dyskinesia, Drug-Induced / Q000209:etiology / Q000473:pathology*; D005260:Female; D006801:Humans; D045586:Intranuclear Inclusion Bodies / Q000378:metabolism / Q000473:pathology*; D007980:Levodopa / Q000009:adverse effects; D008297:Male; D009474:Neurons / Q000378:metabolism / Q000473:pathology*; D020734:Parkinsonian Disorders / Q000188:drug therapy / Q000473:pathology*; D010455:Peptides / Q000378:metabolism; D013624:Taiwan; D025801:Ubiquitin / Q000378:metabolism
D000978:Antiparkinson Agents; D010455:Peptides; D025801:Ubiquitin; C097188:polyglutamine; D007980:Levodopa